Engineered Probiotics Introduced to Improve Intestinal Microecology for the Treatment of Chronic Diseases: Present State and Perspectives

Overview

Journal J Diabetes Metab Disord

Specialty Endocrinology

Date 2023 Nov 17

PMID 37975092

Authors

Jianquan Guo

Bangyuan Zhou

Yali Niu

Liangpo Liu

Liyang Yang

Affiliations

Soon will be listed here.

Abstract

Purpose: Correcting intestinal microecological imbalance has become one of the core strategies to treat chronic diseases. Some traditional microecology-based therapies targeting intestine, such as prebiotic therapy, probiotic therapy and fecal microbiota transplantation therapy, have been used in the prevention and treatment of clinical chronic diseases, which still facing low safety and poor controllability problems. The development of synthetic biology technology has promoted the development of intestinal microecology-based therapeutics for chronic diseases, which exhibiting higher robustness and controllability, and become an important part of the next generation of microecological therapy. The purpose of this review is to summarize the application of synthetic biology in intestinal microecology-based therapeutics for chronic diseases.

Methods: The available literatures were searched to find out experimental studies and relevant review articles on the application of synthetic biology in intestinal microecology-based therapeutics for chronic diseases from year 1990 to 2023.

Results: Evidence proposed that synthetic biology has been applied in the intestinal microecology-based therapeutics for chronic diseases, covering metabolic diseases (e.g. diabetes, obesity, nonalcoholic fatty liver disease and phenylketonuria), digestive diseases (e.g. inflammatory bowel disease and colorectal cancer), and neurodegenerative diseases (e.g. Alzheimer's disease and Parkinson's disease).

Conclusion: This review summarizes the application of synthetic biology in intestinal microecology-based therapeutics for major chronic diseases and discusses the opportunities and challenges in the above process, providing clinical possibilities of synthetic biology technology applied in microecological therapies.

References

Fang X, Zhou X, Miao Y, Han Y, Wei J, Chen T . Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer's disease and Parkinson's disease. AMB Express. 2020; 10(1):80. PMC: 7182653. DOI: 10.1186/s13568-020-01014-6. View

Gitler A, Dhillon P, Shorter J . Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech. 2017; 10(5):499-502. PMC: 5451177. DOI: 10.1242/dmm.030205. View

Chen T, Tian P, Huang Z, Zhao X, Wang H, Xia C . Engineered commensal bacteria prevent systemic inflammation-induced memory impairment and amyloidogenesis via producing GLP-1. Appl Microbiol Biotechnol. 2018; 102(17):7565-7575. DOI: 10.1007/s00253-018-9155-6. View

Yue M, Wei J, Chen W, Hong D, Chen T, Fang X . Neurotrophic Role of the Next-Generation Probiotic Strain MG1363-pMG36e-GLP-1 on Parkinson's Disease via Inhibiting Ferroptosis. Nutrients. 2022; 14(22). PMC: 9698534. DOI: 10.3390/nu14224886. View

Cao W, Dong M, Hu Z, Wu J, Li Y, Xu H . Recombinant NZ3900 expressing bioactive human FGF21 reduced body weight of Db/Db mice through the activity of brown adipose tissue. Benef Microbes. 2020; 11(1):67-78. DOI: 10.3920/BM2019.0093. View

Nadeem M, Kumar V, Al-Abbasi F, Kamal M, Anwar F . Risk of colorectal cancer in inflammatory bowel diseases. Semin Cancer Biol. 2019; 64:51-60. DOI: 10.1016/j.semcancer.2019.05.001. View

Guthrie R, Guthrie D . Pathophysiology of diabetes mellitus. Crit Care Nurs Q. 2004; 27(2):113-25. DOI: 10.1097/00002727-200404000-00003. View

Long R, Zeng W, Chen L, Guo J, Lin Y, Huang Q . Bifidobacterium as an oral delivery carrier of oxyntomodulin for obesity therapy: inhibitory effects on food intake and body weight in overweight mice. Int J Obes (Lond). 2010; 34(4):712-9. DOI: 10.1038/ijo.2009.277. View

Zhang H, Dong M, Yuan S, Jin W . Oral glucagon-like peptide 1 analogue ameliorates glucose intolerance in db/db mice. Biotechnol Lett. 2022; 44(10):1149-1162. DOI: 10.1007/s10529-022-03288-1. View

10.

LILLY D, STILLWELL R . PROBIOTICS: GROWTH-PROMOTING FACTORS PRODUCED BY MICROORGANISMS. Science. 1965; 147(3659):747-8. DOI: 10.1126/science.147.3659.747. View

11.

Mullish B, Quraishi M, Segal J, McCune V, Baxter M, Marsden G . The use of faecal microbiota transplant as treatment for recurrent or refractory infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2018; 67(11):1920-1941. DOI: 10.1136/gutjnl-2018-316818. View

12.

An B, Ryu Y, Yoon Y, Choi O, Park H, Kim T . Colorectal Cancer Therapy Using a SL4 Drug Delivery System Secreting Lactic Acid Bacteria-Derived Protein p8. Mol Cells. 2019; 42(11):755-762. PMC: 6883978. DOI: 10.14348/molcells.2019.0064. View

13.

Smith K . Mental health: a world of depression. Nature. 2014; 515(7526):181. DOI: 10.1038/515180a. View

14.

Martin R, Miquel S, Benevides L, Bridonneau C, Robert V, Hudault S . Functional Characterization of Novel Strains Isolated from Healthy Volunteers: A Step Forward in the Use of as a Next-Generation Probiotic. Front Microbiol. 2017; 8:1226. PMC: 5492426. DOI: 10.3389/fmicb.2017.01226. View

15.

Den H, Dong X, Chen M, Zou Z . Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer's disease or mild cognitive impairment - a meta-analysis of randomized controlled trials. Aging (Albany NY). 2020; 12(4):4010-4039. PMC: 7066922. DOI: 10.18632/aging.102810. View

16.

Cecarini V, Bonfili L, Gogoi O, Lawrence S, Venanzi F, Azevedo V . Neuroprotective effects of p62(SQSTM1)-engineered lactic acid bacteria in Alzheimer's disease: a pre-clinical study. Aging (Albany NY). 2020; 12(16):15995-16020. PMC: 7485699. DOI: 10.18632/aging.103900. View

17.

Tilg H, Adolph T, Gerner R, Moschen A . The Intestinal Microbiota in Colorectal Cancer. Cancer Cell. 2018; 33(6):954-964. DOI: 10.1016/j.ccell.2018.03.004. View

18.

Isabella V, Ha B, Castillo M, Lubkowicz D, Rowe S, Millet Y . Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat Biotechnol. 2018; 36(9):857-864. DOI: 10.1038/nbt.4222. View

19.

Wang L, Liao Y, Yang R, Zhu Z, Zhang L, Wu Z . An engineered probiotic secreting Sj16 ameliorates colitis via Ruminococcaceae/butyrate/retinoic acid axis. Bioeng Transl Med. 2021; 6(3):e10219. PMC: 8459592. DOI: 10.1002/btm2.10219. View

20.

Adolfsen K, Callihan I, Monahan C, Greisen P, Spoonamore J, Momin M . Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering. Nat Commun. 2021; 12(1):6215. PMC: 8553829. DOI: 10.1038/s41467-021-26524-0. View